Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, representing 30-40% of malignant lymphoma cases.
• Gene expression profiling identified two main molecular subtypes: germinal center B-cell (GCB) and activated B-cell (ABC) DLBCL.
• Next-generation sequencing since 2010 has elucidated the genetic mutation landscape in DLBCL.

Purpose of the Study:

• To highlight the distinct molecular pathogenesis of GCB and ABC DLBCL subtypes.
• To underscore the limitations of current treatments like R-CHOP for DLBCL.
• To emphasize the need for novel therapeutic strategies based on molecular understanding.

Main Methods:

• Gene expression profiling to differentiate DLBCL subtypes.
• Next-generation sequencing to identify genetic mutations.
• Review of current treatment regimens and ongoing drug development.

Main Results:

• GCB DLBCL is associated with genetic abnormalities in epigenetic modifiers.
• ABC DLBCL is characterized by constitutive activation of the NF-κB signaling pathway due to specific mutations.
• The R-CHOP regimen remains the standard but requires improvement for intractable cases.

Conclusions:

• Molecular pathogenesis provides critical insights into DLBCL heterogeneity.
• Targeting activated signaling pathways and immune microenvironments is a key area for new drug development.
• Breakthroughs in DLBCL treatment necessitate a deeper understanding of its molecular basis.